Sophia Genetics is partnering with AstraZeneca to apply its multimodal technology and expertise to the biopharmaceutical company’s oncology portfolio.
The multimodal approach will go beyond a single data modality, combining radiomics analysis of medical imaging data, molecular data, digital pathology, clinical and biologic data for a more comprehensive assessment of multimodal signatures leveraging proprietary AI and machine learning technology.
Together, the companies will examine ways to accelerate clinical trials, support evidence generation for market access, and improve clinical decision-making, helping clinicians to select the best possible treatments.
Sophia Genetics has recently launched its own real-world DEEP-Lung-IV clinical study to leverage its multimodal machine learning-powered analytics capabilities to identify multimodal predictive signatures of response to immunotherapy for patients with advanced lung cancer.
“AstraZeneca is a global leader in innovative oncology therapeutics and has built one of the most diverse and robust oncology portfolios and R&D pipelines in the industry. Building on our existing partnership with AstraZeneca, notably to expand access to HRD testing, we are incredibly excited to deepen our collaboration to multimodal approaches that will further enable their precision oncology capabilities,” said Peter Casasanto, Chief BioPharma Officer of Sophia Genetics.
“Multimodality aims to harness the power of advanced AI and machine learning models by integrating multiple data modalities to obtain key insights which inform prognosis and response to therapy at the individual patient level. This approach is synergistic with AstraZeneca’s focus on developing personalised cancer treatment and has the potential to elevate precision oncology, currently driven by genomic-based biomarkers, into a truly multimodal connected health ecosystem,” said Greg Rossi, Senior Vice President, Oncology Europe and Canada, AstraZeneca.
Sophia Genetics is a software company dedicated to establishing the practice of data-driven medicine as the standard of care and for life sciences research. It is the creator of the DDM Platform, a cloud-native platform capable of analysing data and generating insights from complex multimodal data sets and different diagnostic modalities. The DDM Platform and related solutions, products and services are currently used by a broad network of hospital, laboratory, and biopharma institutions globally. For more information, visit sophiagenetics.com.
